

A CARLAT PSYCHIATRY
REFERENCE TABLE

Atypical Antipsychotics With FDA Approval in Bipolar Depression			
Atypical	Approvals in Bipolar	NNT ¹	Dosing Tips
Cariprazine (Vraylar)	Bipolar depression (1.5–3 mg/day). Mania and mixed states (3–6 mg/day).	6–8	For most patients, 1.5 mg/day works as well as 3 mg/day.
Lurasidone (Latuda)	Bipolar depression in adults (20–120 mg/day) and children ≥ 12 (20–80 mg/day). Effective, but off-label, in major depression with mixed features (20–60 mg/day).	5	Most patients take 40–60 mg/day for bipolar depression, and there is weak evidence for a greater response in the 80–120 mg range. Must be taken with ≥ 350-calorie meal to absorb it.
Olanzapine-fluoxetine combo (Symbyax)	Bipolar depression as fluoxetine combo (6 mg olanzapine/25 mg fluoxetine to 12/50 mg daily). Olanzapine is approved for mania and mixed states as monotherapy (5–20 mg/day).	4	Olanzapine does not treat bipolar depression on its own.
Quetiapine (Seroquel XR)	Bipolar depression (300 mg/day). Mania and mixed states (400–800 mg/day).	6	Only the XR is FDA-approved in bipolar depression, but both versions are likely to work, and some patients tolerate the IR version better.

¹Number needed to treat for response in bipolar depression, from Ketter TA, *Advances in Treatment of Bipolar Disorders*, 2015

From the Article
“A New Treatment for Bipolar Depression”
The Carlat Psychiatry Report, Volume 17, Number 8, August 2019
www.thecarlatreport.com